Conference Proceeding

Plasma butyrylcholinesterase activity: a possible biomarker for differential diagnosis between Alzheimer’s disease and dementia with Lewy bodies?.

Nalini D. Josviak

Dementia with Lewy bodies (DLB) is a neurodegenerative disease that affects cognition, behavior and motor function.DLB has extensive deficit in cholinergic neurotransmission, and the cholinergic activity in these patients is more severely impaired than in patients with Alzheimer’s disease (AD). Butyrylcholinesterase (BChE) is an enzyme encoded by BCHE gene, responsible for secondary hydrolysis of the acetylcholine. K and -116A BCHE variants were associated with decrease in plasma BChE activity, and their influence has been investigated in diseases with a cholinergic deficit such as AD and DLB. Despite similar pathologic and neurochemical aspects between AD and DLB diseases and knowing that the cholinergic activity in patients with DLB is more severely impaired than in patients with AD, scarce data is obtainable about BCHE genotypes and BChE activity in DLB. The aim of this study was to compare the plasma BChE activity between DLB, AD and control group, verifying if its activity is associated with the BCHE K and -116A variants.BChE activity was measured using microplate spectrophotometer and all patients and controls were genotyped by TaqMan SNP genotyping assays (Applied Biosystem) for K and -116A variants. We found lower plasma BChE activity in DLB patients compared to elderly controls and to AD independent of the presence of K or -116A variants. Association of genetic variants with BChE plasma activity is discussed for AD, but not for DLB. This study is important because evidence that BChE activity decreases in dementias independently of the genetic variants, with lower peripheral activity still to DLB. This information is relevant for Cholinergicinhibitors treatment and we suggest studies that evaluate the BChE activity potential as a marker. Our results suggest that the reduction of total plasma BChE activity is probably associated with a feedback mechanism and provides a future perspective of using this enzyme as a possible plasmatic marker for differential diagnosis between AD and DLB.

Published: 17 October 2017


Copyright: © 2017 Nalini D. Josviak. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.